Abstract A123: Hallmarks of pharmacodynamic activity of CDR404, a new antibody-derived T cell engager (TCE) targeted against MAGE-A4+ solid tumors in HLA-A*02:01+ patients
Year: 2025
Type: conference-abstract
Source: Molecular Cancer Therapeutics
Authors: Melissa Vrohlings, Matteo Morotti, Daniel Lenherr-Frey, Nikolina Vachtsevanou, Clare Price, Leonardo Borras, Rouven Bingel-Erlenmeyer, Paul Swiecicki, Coral Olazagasti, Rom Leidner, Mark Diamond, Kristoffer Rohrberg, Sylvie Rottey, Hans Prenen, Jean-Pascal Machiels, Nuria Kotecki, Alberto Hernando Calvo, Guillermo de Velasco, Guillermo Suay Montagud, Desamparados Roda Perez, Juan Jesús. Martin Liberal, Matteo Simonelli, Giuseppe Curigliano, Christian Leisner, Swethajit Biswas, Emiliano Calvo Aller
Institutions: University of Michigan, University of Miami, Pennsylvania Hospital, Rigshospitalet, Ghent University Hospital, Ghent University, Antwerp University Hospital, Cliniques Universitaires Saint-Luc, Institut Jules Bordet, Vall d'Hebron Hospital Universitari, Hospital Universitario 12 De Octubre, Hospital Universitari i Politècnic La Fe, INCLIVA Health Research Institute, Institut Català d'Oncologia, IRCCS Humanitas Research Hospital, European Institute of Oncology, Hospital Universitario HM Sanchinarro
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4415444739